Alembic Pharmaceuticals Limited (APLLTD)
Press Release
Alembic Pharmaceuticals expands strategic collaboration with DifGen Pharmaceuticals to grow complex generics portfolio in the US.
- Portfolio includes 20+ differentiated products across multiple dosage forms targeting ~$5bn market.
- Focus on higher value, faster market access with open FTF and Day 1 launch opportunities.
- Initial launches expected from FY28, providing near-term revenue visibility.
- Alembic to manufacture select products; DifGen leads development, regulatory, and US manufacturing.
- Collaboration enhances US manufacturing capacity and commercial platform.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 APLLTD — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add APLLTD to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alembic Pharmaceuticals Limited
Important.
The summary above is generated automatically from Alembic Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.